Celebrex CV risk outweighs cancer benefit
Executive Summary
Final analysis of Celebrex colon cancer prevention studies indicates cardiovascular risk "outweighs what may be an optimistic projection of its potential benefit in decreasing colorectal cancer events," editorial by Bruce Psaty and John Potter states. Pfizer's Adenoma Prevention with Celecoxib (APC) and Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trials were published in the New England Journal of Medicine Aug. 31. Celebrex labeling was updated to reflect the CV results of the trials last year (1"The Pink Sheet" Aug. 8, 2005, p. 6). Editorial also charges studies were too small to evaluate celecoxib's role in preventing colorectal cancer. "It is reasonable to conclude that celecoxib has no role as a chemopreventive agent either in patients with nonfamilial colonic adenomas or in the general population," the editorial concludes...
You may also be interested in...
Pfizer Celebrex Revised Labeling Adds Class Cardio Risk, Moves Safety Data
Pfizer appears to have used the relabeling of its COX-2 inhibitor Celebrex to add class cardiovascular risk language as an opportunity to renegotiate the placement of safety data
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.